Could a One-Time injection of your own immune cells protect your kidneys?

NCT ID NCT06866158

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing whether a single injection of a person's own immune cells (dendritic cells and lymphocytes) can reduce kidney damage in type 2 diabetes. The cells are processed in a lab and then given back under the skin. Researchers will measure urine protein levels and kidney function over four weeks in 80 adults. The goal is to see if this approach can calm inflammation and protect the kidneys.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

autologous dendritic cells and lymphocytes matured with SARS-CoV-2 S protein

What this could lead to

If it works, this could point toward a new way to slow or reverse kidney damage in people with type 2 diabetes, potentially reducing the need for dialysis or transplant.

What could go wrong

This is a very early (Phase 1/2), small, single-arm trial with no placebo group, so results may be due to chance or natural variation. The treatment uses a coronavirus protein to mature the cells, which is unusual and its safety and effectiveness are unproven.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE (DKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gatot Soebroto Central Army Hospital

    Jakarta Pusat, DKI Jakarta - Jakarta, 10410, Indonesia